Status:
ENROLLING_BY_INVITATION
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Lead Sponsor:
Adicet Therapeutics
Conditions:
Lymphoma, Follicular
Lymphoma, Mantle-Cell
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional ...
Detailed Description
This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who received an Adicet Bio allogeneic γδ CAR T cell product that has been genetically engineered to express the an...
Eligibility Criteria
Inclusion
- All patients who received any Adicet allogeneic CAR T investigational product and have either completed the core treatment protocol or have discontinued early
- All patients who are willing and able to adhere to the study visit schedule and other protocol requirements.
- Capable of giving signed informed consent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and protocol
Exclusion
- There are no specific exclusion criteria for this study
Key Trial Info
Start Date :
February 14 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2039
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04911478
Start Date
February 14 2022
End Date
August 1 2039
Last Update
June 9 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Medical Center
Stanford, California, United States, 94305
2
Norton Cancer Institute
Louisville, Kentucky, United States, 40207
3
Baylor Scott & White Research Institute
Dallas, Texas, United States, 75204
4
MD Anderson Caner Center
Houston, Texas, United States, 77030